Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. It offers OMIDRIA, a drug product for use in cataract surgery or intraocular lens replacement designed to reduce complications, to prevent intraoperative floppy iris syndrome (IFIS), and to reduce the need for opioids, pupil-expansion devices, and postoperative steroids. The company also develops narsoplimab, a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. This drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity.